gemfibrozil has been researched along with Obesity in 17 studies
Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
| Excerpt | Relevance | Reference |
|---|---|---|
| " We therefore conducted a double-blind, placebo-controlled, crossover study of gemfibrozil treatment on fibrinolytic function in 21 men with combined hyperlipoproteinemia." | 9.08 | Gemfibrozil treatment of combined hyperlipoproteinemia. No improvement of fibrinolysis despite marked reduction of plasma triglyceride levels. ( Angelin, B; Bröijersen, A; Eriksson, M; Hjemdahl, P; Wiman, B, 1996) |
| "This study investigated the possible synergistic role of obesity in hypertension-induced cardiac remodeling and its modulation by gemfibrozil treatment in rats." | 7.77 | Impact of obesity on hypertension-induced cardiac remodeling: role of oxidative stress and its modulation by gemfibrozil treatment in rats. ( Krishan, P; Singh, AP; Singh, M; Singh, R, 2011) |
| " We therefore conducted a double-blind, placebo-controlled, crossover study of gemfibrozil treatment on fibrinolytic function in 21 men with combined hyperlipoproteinemia." | 5.08 | Gemfibrozil treatment of combined hyperlipoproteinemia. No improvement of fibrinolysis despite marked reduction of plasma triglyceride levels. ( Angelin, B; Bröijersen, A; Eriksson, M; Hjemdahl, P; Wiman, B, 1996) |
| "This study investigated the possible synergistic role of obesity in hypertension-induced cardiac remodeling and its modulation by gemfibrozil treatment in rats." | 3.77 | Impact of obesity on hypertension-induced cardiac remodeling: role of oxidative stress and its modulation by gemfibrozil treatment in rats. ( Krishan, P; Singh, AP; Singh, M; Singh, R, 2011) |
| "Obesity is associated with cognitive impairments." | 1.35 | Obesity and hypertriglyceridemia produce cognitive impairment. ( Abdul, HM; Banks, WA; Butterfield, DA; Farr, SA; Miller, NE; Morley, JE; Xu, L; Yamada, KA, 2008) |
| "Gemfibrozil treatment in non-PiZ patients also resulted in a reduction of alpha 1-AT activity which could be reproduced in vitro." | 1.29 | An interaction between Gemfibrozil and alpha 1-antitrypsin. ( Eriksson, S; Janciauskiene, S, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (41.18) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 1 (5.88) | 24.3611 |
| 2020's | 2 (11.76) | 2.80 |
| Authors | Studies |
|---|---|
| Thongnak, L | 1 |
| Pengrattanachot, N | 1 |
| Promsan, S | 1 |
| Phengpol, N | 1 |
| Sutthasupha, P | 1 |
| Jaikumkao, K | 1 |
| Lungkaphin, A | 1 |
| Kayıkçıoğlu, M | 1 |
| Shahbazova, S | 1 |
| İbrahimov, F | 1 |
| Can, LH | 1 |
| Singh, R | 1 |
| Singh, AP | 1 |
| Singh, M | 1 |
| Krishan, P | 1 |
| Després, JP | 2 |
| Lemieux, I | 1 |
| Pascot, A | 1 |
| Alméras, N | 1 |
| Dumont, M | 2 |
| Nadeau, A | 1 |
| Bergeron, J | 2 |
| Prud'homme, D | 2 |
| Angulo, P | 1 |
| Törüner, F | 1 |
| Akbay, E | 1 |
| Cakir, N | 1 |
| Sancak, B | 1 |
| Elbeg, S | 1 |
| Taneri, F | 1 |
| Aktürk, M | 1 |
| Karakoç, A | 1 |
| Ayvaz, G | 1 |
| Arslan, M | 1 |
| Dufour, JF | 1 |
| Oneta, CM | 1 |
| Farr, SA | 1 |
| Yamada, KA | 1 |
| Butterfield, DA | 1 |
| Abdul, HM | 1 |
| Xu, L | 1 |
| Miller, NE | 1 |
| Banks, WA | 1 |
| Morley, JE | 1 |
| Tenkanen, L | 1 |
| Mänttäri, M | 1 |
| Manninen, V | 1 |
| Janciauskiene, S | 1 |
| Eriksson, S | 1 |
| Nemeth, A | 1 |
| Szakmary, K | 1 |
| Kramer, J | 1 |
| Dinya, E | 1 |
| Pados, G | 1 |
| Fust, G | 1 |
| Huettinger, M | 1 |
| Bröijersen, A | 1 |
| Eriksson, M | 1 |
| Wiman, B | 1 |
| Angelin, B | 1 |
| Hjemdahl, P | 1 |
| Hung, YJ | 1 |
| Pei, D | 1 |
| Wu, DA | 1 |
| Kuo, SW | 1 |
| Fuh, MM | 1 |
| Jeng, C | 1 |
| Mauriège, P | 1 |
| Nerbrand, C | 1 |
| Nyberg, P | 1 |
| Nordström, L | 1 |
| Samsioe, G | 1 |
| Ditschuneit, HH | 1 |
| Flechtner-Mors, M | 1 |
| Hagel, E | 1 |
| Ditschuneit, H | 1 |
| Fasching, P | 1 |
| Ratheiser, K | 1 |
| Waldhäusl, W | 1 |
| Rohac, M | 1 |
| Vierhapper, H | 1 |
2 reviews available for gemfibrozil and Obesity
| Article | Year |
|---|---|
Current best treatment for non-alcoholic fatty liver disease.
Topics: Antioxidants; Chromans; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus; Fatty L | 2003 |
[Alcoholic and non-alcoholic steatohepatitis].
Topics: Alcoholism; Biopsy; Cholagogues and Choleretics; Diagnosis, Differential; Fatty Liver; Fatty Liver, | 2004 |
7 trials available for gemfibrozil and Obesity
| Article | Year |
|---|---|
Gemfibrozil reduces plasma C-reactive protein levels in abdominally obese men with the atherogenic dyslipidemia of the metabolic syndrome.
Topics: Adult; Body Constitution; C-Reactive Protein; Coronary Artery Disease; Gemfibrozil; Humans; Hyperlip | 2003 |
Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study.
Topics: Adult; Blood Glucose; Body Mass Index; Cholesterol, HDL; Coronary Disease; Double-Blind Method; Gemf | 1995 |
Gemfibrozil treatment of combined hyperlipoproteinemia. No improvement of fibrinolysis despite marked reduction of plasma triglyceride levels.
Topics: Adult; Aged; Cross-Over Studies; Double-Blind Method; Fibrinolysis; Gemfibrozil; Humans; Hyperlipopr | 1996 |
Effect of a six month gemfibrozil treatment and dietary recommendations on the metabolic risk profile of visceral obese men.
Topics: Adipose Tissue; Area Under Curve; Blood Glucose; Cholesterol; Gemfibrozil; Glucose Tolerance Test; H | 2001 |
Effects of a lipid lowering fibrate and hormone replacement therapy on serum lipids and lipoproteins in overweight postmenopausal women with elevated triglycerides.
Topics: Administration, Oral; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Estr | 2002 |
Postprandial lipoprotein metabolism in obese patients with moderate hypertriglyceridaemia: effects of gemfibrozil.
Topics: Adult; Apolipoproteins; Body Mass Index; Cholesterol; Eating; Fasting; Female; Gemfibrozil; Humans; | 1992 |
[Fish oil as lipostatic factor].
Topics: Adult; Diabetic Angiopathies; Female; Fish Oils; Gemfibrozil; Humans; Hyperlipidemias; Lipids; Male; | 1990 |
8 other studies available for gemfibrozil and Obesity
| Article | Year |
|---|---|
Metformin mitigates renal dysfunction in obese insulin-resistant rats via activation of the AMPK/PPARα pathway.
Topics: AMP-Activated Protein Kinases; Animals; Diet, High-Fat; Gemfibrozil; Insulin; Insulin Resistance; Ki | 2023 |
Cumulative non-HDL-cholesterol burden in patients with hypertriglyceridemia receiving long-term fibrate therapy: Real life data from a lipid clinic cohort.
Topics: Adult; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cost of Illness; Di | 2020 |
Impact of obesity on hypertension-induced cardiac remodeling: role of oxidative stress and its modulation by gemfibrozil treatment in rats.
Topics: Animals; Aorta, Abdominal; Blood Pressure; Cardiomegaly; Dietary Fats; Gemfibrozil; Glutathione; Hea | 2011 |
Effects of PPARgamma and PPARalpha agonists on serum leptin levels in diet-induced obese rats.
Topics: Adipose Tissue; Animals; Dietary Fats; Energy Metabolism; Gemfibrozil; Hypoglycemic Agents; Hypolipi | 2004 |
Obesity and hypertriglyceridemia produce cognitive impairment.
Topics: Animals; Avoidance Learning; Cognition Disorders; Diet, Atherogenic; Excitatory Postsynaptic Potenti | 2008 |
An interaction between Gemfibrozil and alpha 1-antitrypsin.
Topics: alpha 1-Antitrypsin; Drug Interactions; Gemfibrozil; Humans; Hyperlipidemias; Male; Middle Aged; Obe | 1994 |
Apolipoprotein E and complement C3 polymorphism and their role in the response to gemfibrozil and low fat low cholesterol therapy.
Topics: Adult; Aged; Alleles; Apolipoproteins; Apolipoproteins E; Cholesterol; Cholesterol, Dietary; Cholest | 1995 |
Effects of lovastatin and gemfibrozil in subjects with high ratios of total cholesterol to high-density lipoprotein cholesterol.
Topics: Adult; Aged; Anticholesteremic Agents; Blood Glucose; Cholesterol; Cholesterol, HDL; Female; Gemfibr | 1999 |